Patients who took the higher dose of Innovent’s mazdutide for 48 weeks lost nearly 15% of their body weight in a study of more than 610 Chinese people who were either overweight or obese ...

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...